FDA has become more cautious on drug safety, insiders say

11/14/2010 | Reuters

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT